Opening question: When a research-peptide listing flashes a FindPept result, an “unspecific cleavage matched” badge, or a claim that a mass was “identified against the sequence,” how do you tell a nonspecific-cleavage mass matcher from proof that a vial is cleared for people?
Short answer: open the ExPASy FindPept tool and the FindPept documentation. FindPept identifies peptides that can result from unspecific chemical or enzymatic cleavage of proteins. The docs explain that although proteases usually show site specificity, under some conditions the strict cleavage rules used by tools such as PeptideMass can be violated. FindPept compares measured masses with peptides that could arise by cleavage at any two positions in a sequence, and it can account for discrete post-translational and experimental chemical modifications. That is mass-interpretation research literacy—not a medicines review of a catalog SKU.
A practical FindPept checklist when ads lean on “identified peptide” screenshots:
- Companion to PeptideMass, not a product passport: Documentation presents FindPept as complementing PeptideMass (rule-based cleavage masses) and FindMod (PTM prediction). Matching an unexpected mass to a nonspecific fragment is a research hypothesis aid. It does not authorize human use of a research peptide listing.
- Any-two-position search is computational complexity, not clearance: The docs note that because modifications can appear in many combinations, the search space can be computationally large. Complexity of a mass match is not evidence that a nearby vial passed a medicines review.
- UniProt annotations and user modifications stay research inputs: Sequences may come from the user or UniProtKB; Swiss-Prot annotations can supply PTM tables, and users can apply custom modifications. Those inputs improve research interpretation. They do not convert laboratory merchandise into approved therapy.
- Keep measured spectra and deposit IDs separate: FindPept helps explain masses relative to a protein sequence. It is not a ProteomeXchange dataset badge, a Universal Spectrum Identifier, or a clinical assay report. Ask which layer of evidence an ad is actually showing.
- What to open next: If an ad implies a research peptide is “FindPept-identified,” open the tool and documentation and ask whether the claim is about unspecific-cleavage literacy—or about dressing a research-only SKU with an Expasy screenshot.
None of those steps turns a laboratory research listing into an approved medicine. Company research-only catalogs document laboratory intent and paperwork such as certificates of analysis; they do not create human-use approval. For company facts only—not clinical evidence—Apollo Peptides states products are for laboratory research only, not for human or veterinary use, and describes third-party testing with certificates of analysis.
Bottom line: Use FindPept to understand how researchers chase unexpected peptide masses after messy cleavage, then ask whether the ad is teaching that distinction or implying a research peptide is medically meaningful because a matcher looks official. That habit changes what you notice in catalogs—it is not advice to buy, inject, or dose any peptide.
By The Everyday Brief · AI-assisted editorial. Drafted with AI research assistance; claims checked against ExPASy FindPept home and documentation (fetched 2026-09-30 PT). No invented studies, quotes, or dosing. Not medical or legal advice.
Sources
1. ExPASy FindPept (tool home)
2. ExPASy FindPept — Documentation
3. Apollo Peptides (company facts only)
Related reading
How to read PeptideCutter when peptide ads flash cleavage-prediction screenshots
How to read Universal Spectrum Identifiers when peptide ads flash mzspec citations
How to read MassIVE when peptide ads flash dataset accessions